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ABSTRACT
In the 1970s it was demonstrated that opiate-like
receptors were present in the brain of vertebrate animals.
This finding led to the discovery of a long series of
endogenous opioid peptides, which include the enkephalins,
the endorphins and the dynorphi-ns. With these discoveries,
a whole new era of narcotic research began. Hundreds of
scientific papers have been produced regarding the
properties, distribution and pharmacology of these opioid
peptides. In this study, we have attempted to examine the
possible structural and conformational similarities between
morphine and the opioid peptides by using antibodies raised
against morphine. After 6 trials, we were unsuccessful in
producing a monoclonal antibody against morphine. As a
result, the proposed correlation was studied by using poly-
clonal antisera against morphine. The specificities of the
resulting antisera were determined by competition experi-
ments against 1-125 morphine binding using a series of
selected opiate ligands. Our results demonstrated that the
anti-morphine sera bound morphine with high affinity but
showed no recognition for the opioid peptides or their
analogues. However, their partial cross-reactivity with the
two opiate drugs, naloxone and etorphine, suggests that
they were most probably directed at a region near the
C6 of the morphine structure. The fact that they showed no
cross-reaction with the opioid peptides indicates that the
binding sites for morphine in the antisera may be different
from those of the opioid receptor to which both morphine
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CHAPTER I GENERAL INTRODUCTION
1.1 Historical aspects of morphine
Opium has been used as a drug since classical Greek
times, not only because it relieves pain but also because
it gives rise to euphoria. In 1803, the German pharmacist
Seturner achieved the isolation of morphine as one of the
active ingredients of opium. He named the compound after
Morpheus, the Greek god of dreams. Among other derivatives
of opium are codeine, thebaine, narceine, narcotine and
papaverine. From the isolation of pure morphine to the
discovery of its structure by first Gulland and Robinson
(1925) and later. Schopf (1927) took another 120 years. The
total synthesis of morphine by Gates and Tschudi (1952,
1956) confirmed the structure of this molecule in the
early 1950s. However, the benefits derived from the pain-
killing effects of morphine and its derivatives have been
tempered by their toxicity and addictiveness. These
undesirable side-effects have led to an intensive search
for other opiates with the good properties of morphine but
without the bad ones.
1.2 The discovery of the opiate receptor
It has been known for a long time that the opiates
exert their effects at a very limited number of sites in
animals. This fact indicated the presence of specific
opiate receptors located at these sites. In 1973,
following a stereospecific binding technique developed by
Goldstein et al.(1973), three groups of investigators
(Pert and Snyder; Simon,Hiller and Edelman; and Terenius;
1973) independently described saturable stereospecific
binding sites for the opiates in the animal's nervous
system. It was felt at that time that these receptors were
not provided by the animal just to react with exogenous
opiates; rather there should exist an endogenous compound
which interacts with these receptors to carry out a
physiological function. Thus, the years following 1973
were marked by a most intensive search for the endogenous
ligands. And within the next three years, a good number of
endogenous ligands were isolated from various tissues and
subsequently identified.
1.3 The discovery of endogenous opioids
In 1975, Hughes and Kosterlitz et al.(1975) described
the Isolation from pig brain two pentapeptides which com¬
peted in opiate receptor assays and showed morphine—1 ike
activity in in-vitro smooth-muscle bioassays on guinea-
pig ileum (GPI) and mouse vas deferens (MVD). They named






As shown above, the two peptides shared a common
tetrapeptide sequence, Tyr-Gly-Gly-Phe-, varying only in
the C-terminal. Perhaps even more exciting than this disco¬
very was the realization that met-enkepha1 in is contained
within a 91 amino acid pituitary hormone, -lipotropin (jZ-
LPH), and thus the pituitary gland was recognized to be an
important source of opioid peptides. This was correct as
many opioid peptides isolated from the pituitary were
proved to be different fragments of B-LPH.
In 1976, C.H.Li (and later Bradbury et al.) isolated
a peptide which he named -endorphin (-LPH 61-91; also
called C-fragment) from the pituitary gland of a camel.
It was found that the first five residues of -endorphin
are identical with met—enkephalin, and that this peptide
is much more potent than met-enkephalin in both in vivo
and in vitro tests. This was followed by the finding of
two additional peptides: endorphin (y3-LPH 61-76) and
-endorphin (B-LPH 61-77) by other research groups in
the same year (Guillemin et al. 1976; Ling et al. 1976).
Fig. 1.2
•jENDORPHIN
But -LPH is not the only source of endogenous
opioids in the pituitary gland. In 1979, dynorphin was
characterized by Goldstein et al.(1979). This peptide
differs from -endorphin (lower MW, more basic, more potent
in GPI assay, resistant to CNBr) and its thirteen residues
start with 1eu-enkepha1in at the N-terminal.





and dynorphin (with four extra residues:Trp-Asp-Asn-G1n)
Since then, other opioid peptides of less importance wer
also isolated by various research groups (Igarishi 1979
Couri 1981; Udenfriend 1982).
1.4 Families of opioid peptides
With the aid of modern nucleic acid technology, the
opioid peptides can be classified into three different
families: the enkephalins, the endorphins and the
dynorphins. Each family is derived from a genetically
distinct precursor polypeptide and has a typical anatomi¬
cal distribution. These precursors are proenkepha1 in,
proopiomelanocortin (POMC), and prodynorphin, as shown
be low.
Ficr. 1.4
Schematic representation of the structures of the pro¬
tein precursors of the three families of opioid peptides
DOACMlrOUAlIM
PRODYNORPHIN
Each of these precursors contains a number of
biologically active peptides, both opioid and non-opioid,
which havo been found in blood and various tissues. The
POMC contains the amino acid sequence for melanocortin
(tf-MSH), adrenocorticotropin (ACTH) and -lipotropin(?-
LPH). Within the 9-LPH sequence -endorphin and ~M3H are
found. Although -endorphin contains met-enkephalin at its
N-terminal, it is not converted to this peptide; instead,
met-enkephalin comes from proenkepha1 in. Leu-enkepha1 in is
also derived from proenkephalin. Prodynorphin yields five
peptides which contain 1eu-enkepha1 in: (i) Dynorphin A(l-
17) which can be cleaved to (ii) dynorphin A(l-8); (iii)
dynorphin (1-13); and (iv) o(- and (v) -neoendorphins.
The peptides from POMC is mainly in the pituitary and
those from proenkepha1 in and prodynorphin are spread
widely throughout the CNS, where they are often found in
the same region but in different groups of neurons.
1.5 Mu1tipie opioid receptors
Studies of the binding of opiates and opioid
peptides to specific sites in the brain and other organs
have shown the existence of as many as 8 types of opioid
receptors. In the CNS, there are four major types of
receDtors:
(mu): morphine and morphine-like drugsare agonists.
£ (del t a): receptor for enkephalins.
fC. (kappa),: the drug ketocyc 1 azocine and dynorphin
are preferential agonists.
£ (sigma): N—a 1ly1normetazocine is the agonist.
;and there may be sub-types of each of these receptors.
Analgesia has been related to both ft and k receptors,
while psychotomimetic effects have been connected with
receptors, P receptors are thought to be involved in
affective behaviour. With the exception of some types of
6 receptors, the antagonist naloxone is found to bind to
all receptors .but its affinity for yM receptors is the
highest.
The actions of opiate drugs that are now available
are found to react withy!, k and Preceptors, where they
may act as an agonist, a partial agonist, or an
antagonist.
The opioid peptides show a variety of relative
affinities for different types of receptors. For example,
met-enkephalin-arg -gly -leu has equal affinity foryy and
5 sites, but other peptides from proenkopha 1 i n show a
preference for P sites. All the peptides from the
prodynorphin series bind predominantly to k sites, whereas
dynorphin B and dynorphin A(l-8) also bind toJA andp
sites respectively. In the CNS and peripheral tissues,
-endorphin binds to both Aland Preceptors.
1.6 Structure and function of morphine and its analogues
The structure of morphine was first revealed by
Gulland and Robinson in 1925. Since then, many
semisynthetic derivatives have been made by simple
modifications of the morphine or thebaine molecule.
Codeine, with a methyl substitution on the 3-OH, has about
20% of the potency of morphine. Thebaine differs from
morphine in that both OH groups are methylated (3-OMe, 6-
OMe). It has little opioid activity but is a precursor of
several important 14-OH compounds such as oxycodone (3-
OMe, 6-0, 14-OH), and naloxone (3-OH, 6-0, 14-OH, 17-allyl
group). Other derivatives of thebaine such as etorphine
are more than 1000X as potent as morphine. Heroin, which
is 2X morphine in potency, is prepared by acetylation
(-OAc) at C3 and C6 positions. Hydromorphone (6-0),
oxymorphone (6—0, 14—OH), hydrocodone (3—OMe, 6—0) and
oxycodone( please see above) are also made by modifying
the morphine molecule in different ways. In addition,
there are a number of other structurally distinct groups
of drugs with morphine-like activity, and these include
the morphinans, benzomorphans, methadones and phenylpipe-
ridines. All the compounds mentioned above have shown
common features of possessing the phenolic OH at C3, the
benzene ring and the piperidine ring N atom. It is
believed that these functional groups are very important
for eliciting analgesic actions.
The masking of 3-OH of morphine, as in codeine (3-
OMe) results in several fold reduction in potency. In
contrast, the 6-OH group does not seem too important for
opioid activity. Levorphanol, which lacks the alcohol
group at C6, is a more potent drug than morphine.
Moreover, strong acid rearrangement of the C-ring double
bond in morphine or codeine results in the production of
the ketone (6-0): hydromorphone or hydrocodone. Both are
several times more active than morphine and codeine in
opioid activity. Profound effects on analgesic actions
occur when the substituent on N atom varies. For example,
substitution of an allyl group for the methyl group on N
converts the agonist morphine into the antagonist nalor¬
phine. In general, a 14-OH tends to increase opioid po¬
tencies particularly in antagonist series. Substitution of
a 6-ketone in 14-OH series produces molecules with high
opioid activities eg. oxymorphone and oxycodone. Finally,
it is found that the benzene ring, although not essential
for opioid activity, is necessary in most opiates and its
binding at the opioid receptor is augmented by a free 3-OH
group.
1.7 Conformational studies of opioid peptides
One significant point should be made at this stage:
at least two characteristics are found common to the
opioid peptides mentioned so far. They all act like
opiates and they all contain the sequence Tyr-Gly-Gly-Phe-
Met or Tyr-Gly-Gly-Phe-Leu. It is clear from the above
that these are the sequences which display opioid
activities, either as pentapeptides, or as N-terminal
fragments of larger peptides.
After the discovery of the enkephalins, various
attempts were made to explain their steric conformations
using opiate structures as models. Most investigations
were based on the assumption that all five residues of the
peptide might contribute to its steric conformation. In
1976, Horn and Rodgers(1976) proposed that the tyramine
moiety of the Tyr residue, involving the phenolic hydroxyl
group (at C3 position), the benzene ring and the basic N
atom, is the essential feature for opioid activity of the
enkephalin molecule.
Fiq. 1.5
Morphine showing the Tyr moiety (the highlighted portion)
The importance of this moiety was experimentally confirmed
by Schiller et al. (1977). On the basis of structure-
activity studies, they came to conclusion that the
configuration of met-enkepha1 in had to be equivalent to
that of morphine in order to bind to same receptors.
High-resolution NMR spectra carried out by two
groups (Roques et al. 1976; Jones et al. 1976) reported a
solution conformation of the enkephalin molecule
characterized by a P-bend between Gly -Phe stabilized by
a Gly2 (carbonyl)-Met or Leu (amide) hydrogen bonding.
Fig. 1.6
The possible conformation of the enkephalin molecule




However, Bleich and co-workers (1977) found no basis
for such an intramolecular hydrogen bonding. Some of these
conflicting results were explained by Khaled et al.
(1977), who indicated by NMR, UV and circular dichroisrr
studies that the spectral properties of enkephalin
differed at different concentrations. These authors then
proposed two conformations which are both consistent with
the NMR data:
A structure with a Gly -Phe P bend, with an
additional hydrogen bonding between the hydroxyl group of
Tyr and the carbonyl group of Gly,
Fig. 1.7
Conformation of the enkephalin molecule.The arrow in¬
dicates an additional hydrogen bond Jetween the CO
group of GLY and the OH group of TYR stabilizing a





and extended conformation molecules associated by
intermolecular NH-CO hydrogen bonds to form an
tiparallel
-pleated sheet structure, as shown belov,
Fig. 1.8
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One explanation for different enkephalin
conformations shown by various spectroscopic and
theoretical analyses is that these pentapeptides are
highly flexible and capable of having more than one
conformation in solution. In 1983, Camerman et al.(1983)
confirmed the extended conformation by reporting a solid-
state study of leu-enkephalin by X-ray diffraction. He
indicated that the crystal structure of 1eu-enkepha1 in
contains 4 independent enkephalin molecules and much water
and dimethylformamide solvent in the asymmetric unit. The
four enkephalins have extended backbones with the amino
acid side chains above and below the backbone.
Fig. 1.9
Conformations of the four independent pentapeptides com¬
prising the Leu-enkephalin crystal structure asymmetric
unit.
Of parti cu 1 ai interest is that in the same crystal
lattice, the Tyr, Phe and Leu side chains are found to
have different orientations and that the peptide backbone
can assume different conformations depending on
environmental factors.
There is po far only limited information available
about the steric conformation of the larger endorphins.
Hollosi et al. (1977) and Bayley et al. (1977)
independently found that the peptide can be present with
an helix conformation of the sequence between residues
73-89 of -LPH, depending on the environment. These
authors assume a spatial array of the helical stretch and
the non-helical Nf-terminal portion of the molecule. It
was reported that this arrangement might be responsible
for the high resistance of the peptide against enzymatic
degradation.
1.8 Aim of the nresent thesis
After the discovery of endogenous opioid peptides,
much time has been given to the conformational analysis of
these peptides in a search for structural similarities
between the active opioids and the rigid molecule of
morphine. As the two groups are known to compete for the
same receptors and give a similar pharmacological
response, it is reasonable to suggest that an opioid
peptide may mimic the spatial array of active groups of
morphine during binding interactions. However, this
problem is a very difficult one because of the flexible
nature of opioid peptides and their many conformational
forms, especially in solution.
In order to better understand the proposed
correlation, the Hybridoma technique was used so as to
generate a series of monospecific antibodies against
different determinants on the opiate. It was hoped that
with the aid of these specific analysing agents, we would
be able to investigate fully the likely conformation of
opioid peptides at specific antibody binding sites, and to
detect any structural and conformational similarities that
may exist between the two groups. Morphine was used as a
model for the generation of monoclonal antibodies because
it has a rigid skeleton and its conformation has been well
established.
The main advantage of applying Monoclonal Technology
to such studies is that the method offers the availability
of large amounts of homogenous antibodies which can be
standardized and qua 1ity—contro1 led. In addition, the
distinctive specificity of these reagents makes it
possible to analyse precisely any molecule on an epitope-
to-epitope basis. Their ability to detect even single
residue changes at active binding sites provides valuable
information on the fine antigenic structure of the
molecule.
However, it was most unfortunate that in spite of
numerous attempts, there have been no apparent success in
obtaining these highly specific reagents against morphine.
The procedures employed and experimental data will be
given in chapter II of this thesis. Consequently, a
comparison of the structural conformation between opioid
peptides and their analogues and morphine was made with
the use of polyclonal antisera. The results of such
studies will be duly presented in Chapter III.
CHAPTER II PREPARATION OF MONOCLONAL ANTIBODIES TO MORPHINE
This chapter will be mainly concerned with the
attempts to produce monoclonal antibodies specific for mor¬
phine. In the first part of the chapter, experimental
procedures such as the preparation of immunogen and the
establishment of the specific screening assay will be
described in detail. The second part of the chapter will
consist of experimental data produced by each of the six
subsequent fusions and end with a discussion.
2.1 Principle of Hybridoma technology
When an animal is injected with an immunogen,
the animal responds by producing an enormous diversity of
antibody structures directed against different determinants
of the immunogen (Fig. 2.1). Once these are produced, they
are released into the circulation and it is almost
impossible to separate all the individual clones present in
serum. As each antibody is made by individual cells, the
immortalization of these cells by somatic cell fusion
followed by cloning of the appropriate hybrids allows
permanent production of each of the antibodies in separate
culture vessels. The cells can then be injected into animal
to develop myeloma- like tumours. The serum of the tumour
- bearing animals contain large amounts of these monoclonal
antibodies.
Fig. 2.1 Protocol for generation of hybrid cells
producing monoclonal antibodies.
SPtfEN cells (Ir2r34.. .n)
(Djc m
IMMORTALIZATION BY FUSONTO MYELOMA
Myelomaline
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2.2 Experimental procedures for the production of hybridomas
2.2.1 Preparation of immunoaer
Because of its low molecular weight, morphine (MOR)
was coupled to a carrier molecule to increase its immu-
nogenicity. In our studies, two types of carriers were
used for the conjugation: hemocyanin (hem) and bovine
serum albumin (BSA).
2.2.1.1 Preparation of free base
The free base of morphine was crystallized by
precipitation of M0R-HC1 (15 grn) with 2 N NaOH. The
suspension was filtered and dried under vacuum.
2.2.1.2 Synthesis of 6-succinylmorphine
Free MOR was succinylated at the 6-hydroxyl group
by the method of Simon et al. (1972).
3.4 gm of MOR- base and 3.4 gm of succinic
anhydride in 100 ml benzene were placed in a 250-ml flask
fitted with a condenser and heating mantle. After 2 hours
of heat at reflux temperature (0O°C), 3.4 gm of succinic
anhydride was added and reflux was continued for 1 hour.
The reaction mixture was then cooled to room temperature,
the benzene was decanted and discarded, and the residual
benzene was evaporated in a stream of nitrogen. The
residue was dissolved in 40 ml of water and adjusted
to pH 2 with 2 N HC1. After filtration to remove a small
amount of acid-insoluble material, the pH was raised to
9 with 2.5 N NaOH and the solution was filtered to
remove unreacted morphine. The pH was adjusted to 5 with
HC1, and 6-succinyl morphine crystallized on standing at
4 C overnight. Crystals were harvested by filtration and
dried over calcium chloride under reduced pressure. The
yield of 6-succinyl morphine was about 40-50%.
2.2.1.3 Conjugation to a carrier
100 mg of succinyl morphine was dissolved in 0.5 ml
of 50% ethylene glycol and 50 mg of hemocyanin or BSA in
0.5 ml of water was added. 200 mg of 1-ethy1-3-(3-
dimethylaminopropy1)-carbodiimide in 0.5 ml of 50%
ethylene glycol was then added to the mixture and
incubated at room temperature overnight (Fig. 2.2). The
reaction mixture was dialysed at 4 C against 1 litre of
phosphate buffered saline (PBS, pH 7.4), for two .days
(three changes). The dialysed protein solution was.fil¬
tered (0.8 urn filter) and freeze-dried. The dry1 MOR-
conjugate was then weighed, dissolved in PBS, aliquoted
and stored at -20°C. The degree of conjugation was traced
by using 1-125 labelled succiny1-morphine. It was found
that an average of 16 molecules of morphine was conjugated
to one molecule of hemocyanin; in the case of BSA, it was
an average of 6 molecules of morphine to a molecule of
BSA.
Fig. 2.2 Preparation of the succinylmorphine
conjugate.
CH2CH2C-NH-B5A (or hem)
EDC I-ethyl- 3-( 3- dimethyl amino propyl)- corbodiimide
hydrochloride
2.2.2 Immunization of mice
Morphine-hemocyanin conjugate (4 mgml) in PBS was
mixed with an equal volume of complete Freund's adjuvant
and vortexed to prepare a water-in-oil emulsion. The
emulsion (0.2 ml., approx. 400 ug conjugate) was injected
into each of the eight Balbc mice. Subsequent injections
using a similar emulsion prepared with incomplete
Freund's adjuvant were given at two week intervals. After
a total of four injections (one time Complete and 3
times Incomplete), blood samples were taken from the
tail vein, and anti-MOR activity was detected in the
sera by 1-125 morphine RIA method (the same procedure
would be used later for the screening of culture
supernatants). The mouse with the highest titre (i.e. with
antibody activity in serum diluted 1:1000) was given a
final injection without adjuvant (50 ug of immunogen in
0.2 ml PBS, pH 7.4) at 3-4 days before fusion.
2.2.3 Screening assays for monoclonal antibody activity
The whole process of producing monoclonal antibodies
requires a quick, sensitive and simple assay system to
detect the desired clones. In our studies, four different
immunoassay techniques were examined and it was found that
radioimmunoassay (RIA) with the use of a solid-phase
second antibody (Sac-Cel) provided the greatest sensi¬
tivity and reliability in the measurement of specific
antibodies. These test systems will be described in detail
in the followina sections.
2.2.3.1 RIA with iodine,— labelled morphine
( a) Materia 1s;
1. 1-125 morphine tracei
2. Anti-morphine serum (for screening the clones, the
culture sunernatants would he nsnd ineifeadl
3. Donkey anti-mouse immunoglobulins coupled tc
cellulose beads (Sac-Cel, Wellcome, U.K.).
4. RIA buffer: 0.15 M phosphate buffer, pH 7.4,
containing 0.1% BSA (RIA grade, Sigma) and 0.1%
Triton X-100.
( b) Iodination technique:
1 mg of Iodogen was dissolved in 1 ml of
dichloromethane and the solution was
further diluted 1:30 with CHC 1• 30ul of the
diluted Iodogen solution was pipetted into a 1.5 ml
microfuge tube and incubated at 60 C for 1-2 hour to
evaporate the solvent. A morphine solution of 0.2
mgml in 0.1 M phosphate buffer, pH 7.4, was pre-
pared. To the Iodogen-coated tube, 1 mCi of 1-125
(carrier free) was added, immediately followed by 10
ul of the morphine solution. The reaction was
allowed to continue for 11 minutes at room
temperature. At the end of the reaction time, 0.5 ml
of 0.05 M phosphate buffer, pH 7.4, containing 0.5%
Triton and 0.1% sodium meta-bisu1fate, was added.
The reaction mixture was transferred to a clean
microfuge tube and the content was charged into a
prewashed Seppak C-18 cartridge (Waters Associates,
USA) with a 1 ml syringe. After the radioactive
solution had been pushed through, the syringe was
discarded. The cartridge was then washed ten times
with 2 ml of PBS (pH 7.4) using a clean 5 ml
syringe. 1-125 morphine was eluted by five washings
of 2 ml absolute methanol. The highest
radioactivity was collected in the first fraction.
The 1-125 morphine prepared in this manner was
tested and was stored at 4°c until use. For RIA, the
tracer for binding to either mouse or rabbit
antimorphine sera was diluted in RIA buffer to give
104 cpmlOOul. Table 2.1 shows the result of an
iodination procedure performed on 6488.
Table 2.1 Iodination of morphine
Fraction no. Radioactivity(cpm5u1) Time(min.


















( c) Preparation procedure:
1. The serum taken from an immune mouse was diluted to
1. 1nnn 1 •?nnn and 1 -4000 in RTA buffer.
2. 3 dilutions of 1:100, 1:500 and 1:1000 were
prepared from a previously characterized pooled
i cro-ynm=: noeitive COFltrO 1 S.
3. Normal mouse serum at a 1:100 dilution was
prepared. This sample together with a blank buffer
were included as negative controls.
4. During the screening of hybridoma clones, a sample
of the medium or culture fluid, would be used in
place of the Blank.
( d) Assay procedure:
100 ul of antisera and controls were pipetted
into round-bottomed plastic tubes (12x75 mm),
followed by 100 ul of 1-125 morphine tracer. The
mixture was vortexed and incubated at 4° C
overnight. 100 ul of Sac—Cel was added. The samples
were mixed and further incubated at room
temperature for 30 minutes. At the end of
incubation, 1 ml of cold water was added and the
precipitated immunocomp1 ex was centrifuged at 3000
cpm for 15 minutes at 4°C. Supernatants were
discarded and the pellets were counted at 2 minutes
each in a gamma-counter.
The results obtained from a test-bleed
experiment dated 331988 using the Sac-Cel method
are shown in the following table:












































2.2.3.2 ELISA (Enzyme-1inked immunosorbent assay)
( a) MateriaIs:
1. Carbonate-bicarbonate coupling buffer, pH 9.G.
2. Washing buffer: phosphate buffered saline (PBS),
dH 7.4.
3. PBST: PBS containing 0.05% Tween-20.
4. PBSTmilk: PBS containing 0.05% Tween-20 and 3%
dry milk.
5. Enzyme-labelled second antibody: goat anti-mouse
IgG- peroxidase conjugate (Bio-Rad) diluted in PBS
with 0.05% Tween-20 and 0.1% BSA.
6. Substrate solution: O-pheny1enediamine (OPD) 0.8
mgml plus 0.04% H2°2' n citrate- phosphate
buffer. (pH 5.0) prepared by 24.3ml 0.1 M citric
acid+ 25.7 ml 0.2 M Na2HPO+ 50 ml water+ 80 mg
OPD +40 ul H 09.
7. 96-well microtitre plates (NUNC): flat-bottom.
( b) Assay procedure:
200 ul of MOR-BSA conjugate solution (25 ugml
in coupling buffer) was added to each well, and the
plate was stored overnight at 4 C. Unbound antigen
was removed by washing the plate 3X with
PBSTmilk. Excess protein binding sites were
blocked by incubating with 200ul of PBS with 1% BSA
at 37 C for 30 minutes. Following this incubation,
the plate was washed 3X with PBST, and 100 ul of
appropriately diluted antibody solution (or culture
supernatant) was added. The samples were allowed to
incubate at room temperature for 2 hr. At the end
of incubation, the plate was washed 5X with
PBSTmilk, and 100 ul of a 1:3000 dilution of
enzyme-labelled second antibody was added. This was
followed by a further incubation of 1 hr at room
temperature. The plate was then washed 3X with
PBSTmilk and 2X with PBST, and finally 100 ul of
freshly made substrate solution was applied into
the well. After 30 minutes at room temperature, the
reaction was terminated and the absorbance was
mfiflsured on an automated ELISA reader at 492 nm.
( c) ELISA vs RIA in sensitivity
In order to compare the sensitivity of the
ELISA to that of the RIA described in the previous
section, the following experiments were performed.
ELISA
(1) 25 ugml of MOR-BSA conjugate was applied to
the 96-well microtitre plate at 0.2 ml per
we 11.
(2) The serum from an immune mouse served as a
source of antibodies. It was initially diluted
to 1:100 and further diluted to give a series
of eight serial doubling dilutions. The
antiserum was then applied onto the plate in a
vertical direction. At the same time, normal
mouse serum at a 1:100 dilution was added to
the last row as a negative control.
After washing away the serum, the plate
was treated with second antibody and colour
development solution. The results obtained are
shown in Table 2.3.
RIA(Sac-Ce1)
(1) A 1:100 dilution of a previously pooled
mouse antiserum was prepared in RIA buffer as
a positive control.
(2) Normal mouse serum at a 1:100 dilution was
prepared. This sample together with a blank
buffer were used as negative controls.
(3) The serum from the immune mouse was diluted to
1:100 and was prepared in the same way as
above (please see ELISA (2)).
All the samples were prepared in duplicate.
Sac-Cel separation was performed, and the resulting
counts are given in Table 2.3.
Table 2.3 Radioimmunoassay vs ELISA in sensitivity
Snf i hnrlv H i 1 11 f i rn
RIA ELISA























































































A graph of absorbance (OD) plotted as a function of
radioactivity bound (cpm) was produced (Fig. 2.3). The
data suggested that there was a good correlation between
the two assay systems. The correlation coefficient (r) was
0.85.
Fig. 2.3 A plot showing the correlation of ELISA with RI
ELI3A, OD
2.2.3.3 The dot immunobiriding assay
( a) Materia 1s:
1. Mouse anti-morphine serum
2. Working buffer: phosphate buffered saline (PBS), pH 7.4
3. 1-125 morphine solution : PBS,- containing 1-125 morphine
(10J cpmml), 1% Triton X-100,
0.5% Deoxycholic acid (DOC),
0.1% Sodium dodecyl sulfate
(SDS) and 1% dry milk.
4. Bovine serum albumin (BSA)
( b) Assay procedure
A bio-dot apparatus designed in the format of a
96-well microtitre plate, was used (Fig.2.4).
Fig. 2.4 The assembly of a bio-dot apparatus
sample template (upper plate)
plus seal i ng screws (1)
— nitrocellulose membrane (2)
sealing gasket (3)
• gasket sealing support plate (4)
—guide pin
—vacuun reservoir and tube adaptor (5)
r rubber 0-ring (6)
- tubing and flow valve (7)
Samples are applied into the well and drawn through
the nitrocellulose membrane passively. Wells are washed
repeatedly by applying a vacuum. Afterwards, the membrane
is removed and processed for autoradiography.
In our assay, the antiserum was tested at two-fold
fold decreasing concentrations from 1:100 dilution to
1:1600 dilution. Normal mouse serum was prepared in the
same way as control. The samples were applied into the
wells and allowed to drain through the filter under gravi¬
ty (approximately 1 hr). The nitrocellulose membrane was
then removed ,and the excess binding sites on it were
blocked with a PBS solution containing 1% BSA for 1 hr at
room temperature. After blocking, the membrane was
transferred to a large petri dish containing 1-125
morphine solution and incubated overnight at 4 C. At the
end of incubation, the membrane was removed and washed 6X
in PBS containing 1% Triton, 0.5% DOC and 0.1% SDS (30
minutes per wash). Finally the membrane was dried and
autoradiographed at -70°C for 24 hr using an intensifying
screen.
( c) Results:
Several recent reports (Hawkes et al. 1982; Yeoman
et al. 1983) have shown that the dot blotting technique
has been successfully used in the screening of hybridorna
clones. On one nitrocellulose membrane, 96 supernatants
may be rapidly screened, and the assay is said to offer
an equal or greater sensitivity than the ELISA. However,
in our studies, we detected no apparent binding of 1-125
morphine to thg antiserum on the nitrocellulose membrane.
To solve the problem, we doubled the amount of
radioactivity used (i.e. from 10 cpmml to 2 x 10
cpmml), and also extended the exposure time to 48 hr.
The result again proved to be disappointing and it was
thus decided that we should consider other screening
methods as better alternatives.
2.2.3.4 Radioimmunoassay using a microharvester
During the production of monoclonal antibodies, it
is necessary to assay large numbers of wells for
specific antibodies. Ideally the assay should be quick,
sensitive and simple. ELISA fulfils many of these require¬
ments but it is well known that its sensitivity cannot be
compared to that of the RIA.' The experiment procedure
described here is a modification of the Sac-Cel method
which can process up to 96 samples on one microtitre plate
while offering a greater sensitivity than the ELISA.
( a) Materials:
1. 1-125 morphine tracer (10 cpmml).
2. Anti-MOR serum (or culture supernatant).
3. Sac—Cel second antibody.
4. RIA buffer (please see section 2.2.3.1).
5. 96-well PVC plates (used plates).
6. Micro-harvester (Titertek).
( b) Assay procedure:
The mouse antiserum was diluted to a 1:1000
dilution and further diluted to give a series of doubling
dilutions down to 1:32000. The antiserum (100 ul) was
applied onto the 96-well plate in a vertical direction.
1-125 morphine (50 ul) was added to each well. After
mixing gently, the plate was incubated overnight at 4°C.
Sac-Cel (50 ul) was then added and the samples were
further incubated at room temperature for 30 minutes. At
the end of incubation, the wells were washed with PBS (pH
7.4) on a microharvester, and the contents harvested by
suction and filtration. The pellets collected on the
filter paper (harvester filter) were dried and the
radioactivity from each well was measured in a gamma-
counter.
( n) Resu1hs«
The results ohhi haH m' ir~» nrki a .o i=-» ki .t
—Table 2.4 RadioimmunoflRSflv uslna a microharvest.e:





















































It was hoped that with the modified Sac-Cel method,
we would be able to avoid the time-consuming steps of
sample manipulations and centrifugations. However, our
data suggested that the sensitivity of this assay was
somewhat lower than expected. The experiment was repeated
twice and there was only a slight improvement in the
results. The reason for this could be due to the uneven
washing of the wells by the microharvester. It was
difficult to maintain a constant speed and control
during the washes, and this could have affected the
sensitivity of the assay considerably.
2.2.3.5 Surnmarv of screenina assavs
The initial screenings of hybridomas are usually
performed with hundreds and even thousands of assay sam¬
ples that contain low amounts of antibodies. The main
factors to be considered during the screening process are
sensitivity, simplicity, speed and reliability. In our
studies, it was found that while ELISA offered speed and
simplicity, it was not very sensitive, with a high non¬
specific assay background. In contrast, the Sac-Cel
method was sensitive, fast, easy to perform, and the data
obtained was consistent as compared to those produced by
other screening systems. Thus the Sac Ce1 RIA was
selected for the detection of monoclonal antibody activity
as it better satisfied the main factors mentioned above.
2.2.4 Cell lines and culture media
NS-1 myeloma cells were kindly supplied by
Department of Miprobio1ogy, University of Hong Kong. The
cells were maintained in RPMI 1640 medium supplemented
with 10% foetal calf serum (FCS) (both from GIBCO). The
growth medium also contained penicillin (50 unitsml) and
streptomycin (50 ugml). The cells were grown at 37°C in a
humidified atmosphere with 7% C0o. They were maintained in
optimal conditions (i.e. in logarithmic phase of growth)
for at least one week before fusion was performed.
2.2.5 Cell fusion and culturincr
The fusion procedure follows the basic principles of
Kohler and Milstein (1976). Spleen was removed from the
immune mouse and splenocytes were fused with NS-1 myeloma
cells using 50% polyethylene glycol (PEG 4000, Merck).
Fused cells were suspended in 30 ml culture medium (RPMI-
1640 supplemented with 10% FCS, penicillin and
streptomycin) and incubated in a large culture dish (90
mm) at 37°C for eight hours. A 100 x HAT stock selective
medium containing hypoxanthine
aminopterin and thymidine was prepared. At
the end of incubation, the fused cells were dispensed into
3 x 96-well tissue culture plates (NUNC) containing 0.1 ml
of 2 x HAT medium per well. Approximately 0.5 x 10 fused
cells were placed in each well. When hybridoma growth had
reached about one third of the well, the culture
supernatant was taken and tested by the Sac-Cel RIA method
(Section 2.2.3.1). This usually occurred between 10-14
days after fusion.
2.2.6 Cloning of hybridomas by Limiting Dilution
Hybridomas producing antibody which bound 1-125
morphine were cloned by limiting dilution. Cells were
plated in a 96 well plate at the following concentrations:
36 wells with an average of 5 cells well, 36 wells with
an average of 1 cellwell and 24 wells with an average of
0.5 cellwell. Approximately 0.5 x 106 splenocytes were
added into each well as feeders.
2•3 Experimental—data for the production of hybridomas
Altogether six fusions were performed in this study.
A total of 749 wells containing growing hybridoma cells
were observed. 49 of these scored positive upon initial
screening by the Sac-Cel RIA method. The results, together
with other relevant information, are presented in the
following sections:
Fusion experiment A: Twenty-five million NS-1 cells were
mixed with 188 x 106immune spleen cells in a 50 ml
conical tube, and plain medium (RPMI 1640, GIBCO,
supplemented with penicillin and streptomycin) was added
to a volume of 30 ml. The cell mixture was centrifuged at
1100 rpm for 5minutes and was washed once more in plain
medium. After contrifugation, the supernatant was
carefully removed and the cell pellet was loosened by
gentle tapping of the tube. 1 ml of pre-warmed 50% PEG
solution was added dropwise in 1 minute, with occasional
gentle shaking. Two ml of warm plain medium was then added
dropwise over a 2 minute period, followed by a further 10
ml over the next 5 minute period. The cell suspension was
contrifuged at 1200 rpm for 10 minutes. After removal of
the supernatant, the cell pellet was gently suspended :in
30 ml plain medium containing 10% FCS and incubated for 0
hours. At the end of incubation. the fused sells wer-e
dispensed into 384 microtiter Dlate wells ai
cellswell in HAT medium (see Section 2.2.5). The cultures
were fed on day 7 and every 3-4 days afterwards. Small
colonies of hybrid cells were microscopically visible
between 7-10 days. As soon as cell colonies grew to about
one third of the well, 0.1 ml supernatant was taken and
screened for antibody activity.
Table 2.5 shows that in this experiment, 8 out of
143 wells (0.06%) containing hybrid colonies produced
antibodies which bound 1-125 morphine with an affinity of
%
about 1.2x background reactivity. Hybridomas from 5 of
these wells with the highest antibody activity were choser
and cloned by limiting dilution (for details of the
method, please see Section 2.2.6). From these, 2 wells
were assayed positive for antibody production. They were
subsequently recloned, and in each case the hybrid
colonies obtained were found to be totally negative.
Table 2.5 Results of fusion experiment A


















































total number of wells seeded
well with hybridoma growth
wells with antibody-secreting hybrid cells
wells with non-producers
= positive signal secreted by hybrid cells
(please see Section 2.2.3.1 for assay procedure
ion—experiment B: Twenty—f ive million NS— 1 cells were
fused with 125x10 immune spleen cells. The fusion mixture
was distributed into 384 wells at 0.4xl06 cellswell in
HAT selective medium containing 10J splenocytes as feeder
cells. The data obtained from the first screening on day
10 were found to be totally negative, as shown in Table
2.6. Meanwhile, it was observed that the growth of the
hybrid colonies was very slow, with a large number of
fibroblasts and macrophage—1 ike cells spreading at the
bottom of the wells. A second screening 4 days later again
resulted in a negative finding. The attempt was finally
abandoned after 19 days of culture.
Table 2.6 Results of fusion experiment B





384 91 0 91
Please see footnotes of Table 2.5 for explanation
Fusion experiment C: Thirty-four million NS-1 cells were
fused with 175xl06 immune spleen cells using 50% PEG. The
resulting cell mixture was dispensed into 288 wells at
0.7x10 cellswell in HAT medium. Table 2.7 shows that 8
out of 136 wells (0.06%) with hybrid growth were found
positive with an affinity of 1.2x background reactivity.
One well showing the highest antibody secretion (i.e.
positive by 2 successive screenings) was selected for
subcloning. Thirty wells with hybrid colonies were
obtained. Six of these (0.2%) were positive for antibody
activity, from which 2 wells were chosen for further
subcloning: 1(a) and 1(b). In the case of 1(a), 3 out of 9
wells were initially identified positive (1.4x background
reactivity), but these 3 wells lost antibody production on
second screening. In the case of 1(b), 6 out of 29 wells
scored positive (1.3x background reactivity) but again all
yielded negative results on the second screening.
Table 2.7 Results of fusion experiment C




























Please see footnotes of Table 2.5 for explanation.
Q indicates a loss of signal on rescreening by RIA.
FusT.Q.0 experiment D: Seventeen million NS—1 cells were
fused with 110x10 immune spleen cells. The fused cells
were distributed into 320 wells at 0.4xl06 cellswell in
HAT medium. As indicated in Table 2.8, 12 out of 81 wells
(0.15%) with hybrid growth were positive for antibody
activity(1.4x background reactivity). Hybridomas from 7 of
these wells were chosen for subcloning by limiting
dilution: I—VIII. Wells I and V were subcloned in
duplicate. Subsequently, in 1(b) 5 of 43 wells with
hybridoma growth were positive(1.3x background
reactivity), however, they all lost antibody activity on
second screening. The same was observed in subclones II
and III; in the former case, 3 out of 54 wells scored
• positive (1.3x background reactivity) on initial
screening, and in the latter, 2 out of 51 wells were
positive(1.4x background reactivity). During the course of
the experiment, cultures IV, VI and VII were overgrown by
macrophage and fibroblast cells, thus resulting in no
hybrid growth. On the other hand, although hybrid colonies
were obtained from 1(a), V(a) and V(b), they were found to
be negative for antibody production.
Table 2.8 Results of fusion experiment D
















































Please see footnotes of Table 2.5 for explanation.
Please see Table 2.7.
Fusion experiment E: Forty-four million NS-1 cells were
fused with 176x10 immune spleen cells. The cell mixture
was dispensed into 480 wells at 0.45xl06 cellswell in HAT
medium. As indicated in Table 2.9, 6 out of 76 hybrid
cultures (0.07%) were shown positive. From these, 3 wells
were chosen for subcloning by limiting dilution; I-III. In
I, 58 wells with hybrid growth were obtained. 9 of these
wells(0.15%) were found to be positive for antibody
activity, from which 5 wells were selected for further
subcloning; 1(a)- 1(e). Since II yielded no hybrid
growth, the plate was discarded after 2 weeks. In III, 10
out of 27 wells (0.4%) had antibody activity, from which 3
wells were chosen for further subcloning; 111(a)- III(c).
However, all of the hybrid colonies subsequently generated
from the second limiting dilution were found to be totally
negative.
Table 2.9 Results of fusion experiment E






















































Please see footnotes of Table 2.b tor explanation.
fusion—experiment F: Twenty—eight million NS—1 cells were
fused wi th 150x10 immune spleen cells. Tlie cell mixture
was distributed into 336 wells at 0.5xl06 cellswell in
HAT medium. Table 2.10 shows that 15 of the 222 wells
(0.06%) with hybrid growth were identified positive for
antibody production. From these, 6 wells were chosen for
subcloning by limiting dilution. On initial screening of
the subcloned cultures, only one well from IV was
positive(1.3x background reactivity). However, the hybrids
in this well lost all antibody activity on second
screening.
Table 2.10 Results of fusion experiment F

































Please see footnotes of Table 2.5 for explanation
Please see Table 2.7.
2.4 Discuss ion
Six fusions were performed during the preparation of
monoclonal antibodies against morphine. In our studies, a
positive culture was screened twice before it was
subcloned by limiting dilution. As can be observed from
our results, a good number of clones which -were initially
positive lost antibody activity after the first screening.
This problem continued to exist even after we had
subcloned the cultures which were confirmed to be positive
by two -successive screenings. It was found that of the
many hybrid clones generated after limiting dilution, a
majority gave negative results, with only a few yielding
weakly positive signals. Moreover, the initial weakly
positive hybrid cell lines soon lost all antibbody
production and became non-producers. This mostly occurred
before the second screening of the subcloned hybrid cells.
The situation was not helped by a further subcloning of
these cultures. In short, although we managed to obtain a
good number of positive clones after a fusion, we somehow
found it difficult to generate a stable cell line out of
these hybrid cultures.
To overcome this difficulty, we are at present
considering some other strategies which may be helpful ir
obtaining successful results. It has been estimated that
the splenocytes needed for a fusion contain only a small
subset of the heterogeneous spleen cell populations,
approximately 1%. Thus for a mouse spleen of 10 cells,
only 10 cells will be actually secreting the desired
antibody. According to a published study (Scharff et al.,
1980), one successful hybrid can be formed per 2xl05 of
these splenocytes. Therefore if 1?6 of the 10 spleen cells
can secrete the right antibody, five desirable hybridomas
will be generated from one spleen. This is correct when
applied to- highly immunogenic molecules, but for less
immunogenic antigens such as morphine conjugates, the
number of hybridomas formed from a mouse spleen will be
much less.
Based on this theoretical extrapolation, we
propose that in the future, splenocytes from 3-4 immune
mice may be fused at the same time and plated out in a
large number of 96-well tissue culture plates. In order to
speed up processing so many cultures at a time, the
screening will be done in two steps; firstly by ELISA then
followed by RIA. Basically the procedure involves a quick
ELISA to select potential hybrid cultures. Then these will
be rescreenecl by RIA at a later stage. Moreover, the high
assay background inherently associated with ELISA can be
minimised by running two sets of ELISA's. For the determi¬
nation of antibodies to morphine, MOR-hemocyanin coated
plates are used and for the determination of antibodies to
hemocyanin, hemocyanin coated plates are used. By
comparison of the results from the two assays, antibodies
recognizing the hemocyanin moiety of the MOR-hemocyanin
conjugate can be eliminated. The positive cultures
obtained in this manner can then be confirmed by the more
specific RIA (using Sac-Cel) procedure.
Anobher possible method to successfully obtain
hybridomas may be to use a different myeloma cell line for
fusion. It is well known that NS-1 synthesizes k light
chain and that NS-1 fusion hybrids will secrete molecules
incorporating this light chain (Hurrell, 1982). As a
result, only one immunoglobulin molecule in four will be
actively coded for by the spleen parent, the other three
will have low or no binding affinity for the antigen. On
the other hand, a non-producing myeloma line synthesizes
neither heavy nor light chains and therefore produces
hybridomas which will make only the spleen cell antibody.
The most common non-producing myeloma lines are listed in
Table 2.11 below, together with the NS-1 line for the
comparative purpose.
Table 2.11 Myeloma lines which have been success
fully used in hybridoma production



























Another good approach to increase the probability of
generating a successful hybridoma, is to have morphine
coupled to hemocyanin in different ways. The advantage of
6-succinylrnorphine is the availability of all functional
groups essential for pharmacological activity. Coupling is
done via the 6-OH group, which is unnecessary for opioid
activity. In a recent paper, Findlay et al. (1981) has
reported that the attachment of the MOR molecule to a
carrier at a site close to, but distinct from the N atom
(i.e. at C2 or C8 positions), may lead to antiserum with
the best overall specificity characteristics. The
resulting antiserum is said to be very sensitive to
changes in structure at C3 or C6 positions, as well as at
the N atom. It will certainly be of great interest to see
whether a different morphine conjugate may enhance the
possibility of obtaining successful monoclonal antibodies.
CHAPTER III The production and use of polyclonal
antibodies specific for morphine
3.1 Introduction
As has already mentioned, morphine and opioid
peptides are found to bind to the same opioid receptors in
the brain. Surely there must exist some kinds of
structural similarities between the opiates and their
endogenous peptides. It was originally hoped that this
investigation would be carried out by using a panel of
monoclonal antibodies directed against different
determinants of the morphine molecule. However, since we
had no success so far in producing these highly specific
reagents, polyclonal antisera specific for morphine from
rabbits and mice were used as alternatives to test our
original hypothesis. The specificity of each of these
antisera was characterized by its ability to bind to a
range of related opiate ligands in the radioimmunoassay
system.
3.2 Materials and Methods
3.2.1 Antiserum preparation.
Rabbits were injected subcutaneously at multiple
sites in the back with morphine-hemocyanin conjugate (1
mgrabbit) in 1 ml phosphate buffered saline (PBS, 0.15M
NaCl, 0.01M phosphate buffer, pH 7.4) emulsified with an
equal volume of complete Freund's adjuvant. Five to six
additional booster injections in incomplete Freund's
adjuvant were given similarly at 2 week intervals. Blood
was collected from the median artery of the ear after one
week. Two samples of rabbit anti-morphine antiserum were
obtained as a result of immunization and these were
designated as RB 3 and RB 4. For the preparation of mouse
anti-morphine antiserum, please see Section 2.2.2 of Chap¬
ter II. Six sera were produced and numbered MOS 1- MOS 6.
3.2.2 RIA procedure.
( a) Materials.
1-125 morphine tracer (10 cpmml).
Donkey anti-mouse antisera coupled to cellulose
beads (Sac-Cel, Wellcome, U.K.).
Rabbit IgG, concentration- 30 mgml. For working,
dilute lOOx with RIA buffer.
Goat anti-rabbit serum (P3). One ml will precipitate
3 mg IgG. For working, dilute lOx in RIA buffer.
RIA buffer: 0.15M phosphate buffer, pH 7.4, contain¬
ing 0.1% BSA (RIA grade) and 0.1% Triton X-100.
( b) Assay method.
Antiserum titres were determined by incubating 0.1 ml of
various dilutions of antiserum in RIA buffer with 0.1 ml
of 1-125 morphine tracer, and a further aliquot of 0.1
ml RIA buffer. Incubation was carried out at 4 6 C
overnight. For the mouse antiserum, antibody-bound
radiotracer was precipitated by incubation for 30
minutes at room temperature with 0.1 ml Sac-Cel. After
the addition of 1 ml distilled water, the tubes were
centrifuged at 3000 rpm for 15 minutes. The supernatants
' were removed and the pellets were finally counted at 2
minutes each in a gamma counter. The optimal titre
chosen was the dilution which bound 20-40% of the total
radioactive tracer added. Fig. 3.1 summarizes the titres
of each of the mouse anti-morphine serum. The optimal
dilutions chosen are summarized in Table 3.1. For the
rabbit antiserum, the samples were prepared and
incubated in the same way as described above, except
that on the next day, 0.1 ml rabbit IgG and 0.1 ml goat
anti-rabbit antiserum were added to each sample, and
O
incubation was carried on for another night at 4 C. On
the third day, 1 ml cold PBS, pH 7.4, was added, and the
tubes were then centrifuged at 5200 rpm for 45 minutes.
The pellets eventually collected were counted at 2
minutes each in a gamma counter. The results of the
rabbit samples are shown in Fig. 3.2. The optimal
dilutions chosen for RB 3 and RB 4 were 1:1600 and
1:3200, respectively.
3.2.3 Selection of opiate ligands.
( a) Rationale
A group of opiate-like compounds was selected and used as
unlabel led ligands in the competition experiments against
1-125 labelled morphine for binding sites in the
antibodies. Studies on the binding of the various opioids
%
have shown that morphine, which is the standard drug for
producing analgesia, is a potent agonist for tYe p-binding
receptor (Martin, 1976). On the other hand, naloxone is a
competitive antagonist at thep-r i-, and k- sites but
its binding to the p -site is considered to be the most
selective (Lord, 1977). Etorphine, being 700x more potent
than morphine in human and lOOOx more potent in animals
(Lister, 1967), has the highest»affinity for the k-site
(Robson, 1902). Apart from the 3 drugs mentioned above,
some of the endogenous peptides and their synthetic
analogues were also included in this study, -endorphin is
found to be equipotent in displacing the binding of
tritiated J- or -ligands (Kosterlitz, 1982). Both met-
enkepha1 in and its stable analogue, [D-Ala2, D-Leu5]-
enkephalin (DADLE), bind predominantly to the o-site
(Kosterlitz, 1982). A C-terminus extension of leu-
enkephalin results in the formation of leu-enkephalin-arg.
However, this active peptide loses its -selectivity which
is typical of the enkephalin, and shows a marked affinity
for the k-site (Corbett, 1982). Both dynorphin_13 and
dynorphin B interact preferentially with the k-site
(Corbett, 1982), while [D-Ala, MePhe4, Gly-o15]-enkepha¬
lin (DAGO) is a -selective ligand, being 220 times more
active at the J -than at the -binding site (Kosterlitz,
1981). Table 3.2 summarizes the properties of the opiate
ligands selected for our study. It is expected that these
ligands would provide a good spectrum of structural
features which will enable us to dissect the similarity of
morphine with them in the binding to distinct sub-types of
the opioid receptors.
Table 3.2 List of opiate ligands used in this study






































































The affinity of unlabel led opioids was estimated as the
inhibition constant (Ki) from their ability to displace
the binding of labelled ligands of known characteristics.
For each ligand the potency at the site for which it had
highest affinity was taken to be 1.
( Ref.: Hughes, J (1983) ed. Opioid peptides,
Churchill Livingstone, pp.32-34).
NA: data not available.
( b) Method of assay
The affinity of anti-morphine antisera to recognize
different opiate ligands was determined in competition
studies in which varying concentrations of the cold
ligands were used to displace 1-125 morphine from the
antibodies. Serial dilutions of the unlabelled ligands
were prepared by a 3-fold dilution from 104 nM to 0.056 nM
in RIA buffer. The appropriately diluted opiate ligand
(0.1 ml) was incubated with 0.1 ml 1-125 morphine and 0.1
ml antiserum of the chosen titre. The tube that contained
1-125 morphine and antiserum but no unlabelled ligand
served as a measure of the maximum antibody-bound
radioactivity (D). A control containing no antibody was
used as the blank. Incubation conditions and separation of
bound and free radioactivity were as described in 3.2.2.
All the binding data are expressed as BBo in which B is
equal to activity bound minus blank and Bo is the maximum
activity bound minus blank.
3.3 Results
( a) Optimization of antiserum titres.
Antisera were used at optimal dilutions required to
bind about 20-40% of 1-125 morphine in the absence
of a competing ligand. The results are shown in Fig.
3.1 and Fig. 3.2 respectively. Table 3.1 summarizes
the optimal antibody dilutions of the mouse samples.
Fig. 3.1 Determination of antibody titref
in mouse samples
Antibody dilution (-fold Antibody dilution (-fold) Antibody dilution (-fold)
Antibody dilution (-fold; Antibody dilution (-fold)
Antibody dilution (-told
Antibody dilution (-fold)
Table 3.1 Optimal antibody dilutions of mouse samples













Fig. 3.2 'Determination of antibody titres
in rabbit samples
Antibody dilution (-fold; Antibody dilution (-fold)
Antibody dilution (-fold)
( b) Competition experiments.
In our studies, 2 rabbit antisera together
with 6 mouse antisera were produced. The specificity
of the antibodies was examined by competitive
radioimmunoassay with 1-125 morphine against a
series of opiate ligands. Our results demonstrated
that these antisera were quite similar to each other
in that they all bound morphine with high affinity.
Some recognition was also observed with high concen¬
trations of the opiate antagonist, naloxone, and the
opiate agonist, etorphine. However, there was no
measurable cross-reactivity with the endogenous
opioid peptides or their synthetic analogues such as
DADLE and DAGO. The results of these assays are
presented individually in the following sections and
summarized in Tables 3.3 and 3.4.
( i) Mouse anti-morphine serum: MPS 1
Both naloxone and etorphine showed a very small
degree of cross-reactivity with antiserum MOS 1. No
inhibition was obtained with all the opioid peptides
or their analogues even at the highest ligand
concentrations tested. The with standard
50
morphine was at 33.6 nM, and with naloxone and
etorphine were at 49 uM and 230 uM, respectively.
Fig.3.3 Inhibition of 1-125 morphine binding to
antiserum MOS 1 by various opiate ligands. The optimal
dilution of the antiserum used was 1:100. BBo was
defined as the percentage of specific radioactivity
bound to the antiserum in the presence of sample to
the specific radioactivity bound in the absence of the
opiate ligand. 1-125 morphine bound was determined in
thp. nrpqftnnfi of different concentrations of morphine
naloxone (o), etorphine and all opioid
peptides analogues
OPIATES CONG, nM
( ii) Mouse anti-morphine serum: MPS 2
This antiserum was more sensitive and only 3.8 nM of
morphine was required to inhibit 50% of the 1-125
morphine binding. The IC5Q of naloxone and etorphine
were at 2 uM and 23 uM, respectively. Again, there was
no observable cross-reactivity with the endogenous
opioid peptides or their analogues.
Fig. 3.4 Inhibition of 1-125 morphine binding to
antiserum MOS 2 by various opiate ligands. The
optimal dilution of the antiserum used was 1:1600.
Please see Fig. 3.3 for details of symbols used.
OPIATES CONC, nM
( iii) Mouse anti-morphine serum: MPS 3
One very interesting feature in this antiserum is
that it bound etorphine with higher affinity than
the previous 2 antisera. The slope of the binding
inhibition curve was parallel with that of the
standard morphine, indicating that this antiserum
may possess certain binding sites which recognize
similar determinants on morphine and etorphine. The
ICq with standard morphine was at 4.9 nM, and with
etorphine was at 1439 nM. This antiserum also
demonstrated significant cross-reactivity with
naloxone, with value at 450 nM. However, the
inhibition curves obtained with morphine and
naloxone had quite distinctive slopes.
Fig. 3.5 Inhibition of 1-125 morphine binding to
antiserum M0S 3 by various opiate ligands. The
optimal dilution of the antiserum used was 1:200.






iv) Mouse anti-morphine serum: MPS 4
This antiserum showed only slight cross—reactivity
with naloxone and etorphine. The ICc~ with stan-50
dard morphine was at 9.2 nM, and with naloxone and
etorphine were at 10 uM and 235 uM, respectively.
Fig. 3.6 Inhibition of 1-125 morphine
binding to antiserum MOS 4 by various opiate
ligands. The optimal dilution of the antiserum







( V) Mouse anti-morphine serum: MPS 5
The binding of this antiserum to naloxone was
relatively similar to that of antiserum MOS 2 in
Fig. 3.4. The with morphine was at 5.8 nM,
and with naloxone and etorphine were at 6 uM and 77
uM, respectively.
Fig. 3.7 Inhibition of 1-125 morphine binding
to antiserum MOS 5 by various ligands. The
optimal dilution of the antiserum was 1:100.





( vi) Mouse anti —morphine serum: MPS 6
Our results showed that the binding of this
antiserum to naloxone was similar to that of
antiserum MOS 2 in Fig. 3.4 and of antiserum MOS 5
in Fig. 3.7. In contrast to the previous 5
antisera, no measurable inhibition was observed
with etorphine. As before, no binding with other
ligands was detected. The values with
standard morphine was 3.2 nM and with naloxone
was 4 uM.
Fig. 3.8 Inhibition of 1-125 morphine binding
to antiserum MOS 6 by various ligands. The
optimal dilution of antiserum used was 1:3200.




( vii) Rabbit anti-morphine serurn: RB 3
The cross-reactivity of the antiserum to naloxone,
etorphine and opioid peptides was almost
negligible. The 50 morphine was at 1.9 nM
which indicated that the antiserum was by far the
most sensitive in binding to morphine.
Fig. 3.9 Inhibition of 1-125 morphine binding to
antiserum RB 3 by various ligands. The optimal
dilution of the antiserum used was 1:1600. Please
see Fig. 3.3 for details of symbols used.




( viii) Rabbit anti-morphine serum: RB 4
There was hardly any inhibition of 1-125 morphine
binding to this antiserum by naloxone, etorphine
and other opioid peptides. The with morphine
was 4.6 nM.
Fig. 3.10 Inhibition of 1-125 morphine bindinc
to antiserum RB 4 by various ligands. The optima]
dilution of the antiserum used was 1:3200.




Table 3.3 5Q °f opiate ligands for
inhibition of 1—125 morphine
binding to various antisera.










































IC,-n: ligand concentration required to inhibit 50% o.
1-125 morphine binding.
k NI: no inhibition at the highest opiate ligand
concentration tested (i.e., 0.1 mM).
jl
Table 3.4 Cross-reactivities{%) of opiate ligands
with various anti-morphine sera.











































'Cross-reactivities were determined as the percentage ratio
of the IC,-n of morphine and the IC of the opiate ligand. I•% jU 3 u
tested.
MT• PI Pflc-p Tnhle 3.3.
3.4 Discussion
Polyclonal antisera were raised to morphine-
hemocyanin conjugate with the aim of producing a
recognition site which may interact with the opioid
receptor binding determinant of the opioid peptides. In
the present study, an attempt was made to identify these
binding sites for various opiate ligands in the anti-
morphine sera by competitive binding with 1-125 morphine.
In order to investigate the specificity of the binding,
the ability of these opiate ligands to compete with the
radio-ligand for binding to the antibody recognition sites
was compared. Our results indicated that the antisera
raised in rabbits had a high specificity for the parent
drug, morphine. On the other hand, the antibodies obtained
from the mice demonstrated a wider spectrum of
specificity. In addition to binding morphine, these
antisera also cross-reacted partially with the opiate
antagonist naloxone, and to a lesser degree, with the
opiate agonist etorphine.
It has been shown in previous reports (Martin, 1976)
that morphine is a potentyM-se1ective 1igand for the brain
opioid receptor. This follows that the antiserum raised
against morphine will most probably possess binding sites
which closely resemble the JA -receptor. In turn this
antiserum will be very likely to interact with other
potenty-1igands such as DAGO, -endorphin and naloxone in
the RIA binding assays. However, our results suggested
that this is not the case. It was shown that the antiserum
generated from mice, apart from binding morphine, only
exhibited a limited cross-reactivity with naloxone and
etorphine; in the order of morphine naloxone etorphine.
Contrary to our reasoning, all the pharmacologically
active opioid peptides and their stable analogues had no
displacement of 1-125 morphine in the antiserum. In order
to better understand the interaction of the opiate 1 igands
with the receptor, it is necessary to carefully examine
the binding characteristics of different types of opioid
receptors (please also see Table 3.2). It is shown that at
the JA -binding site of the receptor, where DAGO is a
highly selective agonist, the relative binding affinities
for the 3 alkaloid opiates are in the order of morphine=
naloxone etorphine. At the -site, where DADLE is the
-specific agonist, the order of selectivity is etorphine
naloxone morphine. At the k-binding site, where the
dynorphins are reckoned to be the selective 1igands, the
order for the inhibition of binding is etorphine
naloxone morphine. From these data, it can be seen that
the binding properties of the anti-morphine sera used in
our competition experiments were not identical with those
shown by the 3 types of opioid receptors. This is
different from our expectation, which stipulates that the
antiserum would resemble the Al -receptor in its binding
behaviour. Thus we could conclude at this stage that the
antibody recognition sites for morphine in our antisera
may be quite different from those of the opioid receptor
to which the active endogenous peptides bind with high
affinity. It is highly probable that the opioid receptor
may possess an extensive binding site, of which only one
part will interact with morphine and other structurally
similar opiates. Perhaps, it is this lacl of similarity in
the conformation of the recognition sites which accounts
for' the inability of the antiserum to cross-react with the
opioid peptides.
The fact that the anti-morphine sera cross-reacted
partially with the 2 opiate drugs indicate that, in
general, these antibodies recognized ligands containing a
basic morphine structure. As shown in Fig. 3.11 below,
naloxone only differs from morphine in the possession of a
hydroxy 1 group at the C14 position, a carbonyl group at
the C6 position, as well as the substitution of an N-
methyl group by an allyl group. On the other hand,
etorphine is synthesized from morphine by having its C6
and C7 positions substituted by different functional
groups.
Fig. 3.11 The molecular structures of morphine
naloxone and etorphine.
The results of our experiments suggested that the
antibodies showed no recognition for the region around the
tyramine fragment, i.e., the part containing the phenolic
hydroxyl group and the benzene ring. If this is not the
case, there should be a marked cross-reactivity between
the three opiate drugs tested. It is apparent that these
antibodies were perhaps more selective for the region in
the lower half of the morphine molecule, i.e., at the C6,
C7. N17 sites (Fig. 3.11). Here the molecular structures
between morphine, naloxone and etorphine are considerably
different from each other. It is very likely that the lack
of structural similarity in this area had contributed to
the small degree of cross-reactivities obtained in our
studies. Finally since we were interested in antibodies
which mirnic the receptor binding site, it may be
worthwhile to try to produce additional anti-morphine
antisera through different conjugation procedures, and to
compare their specificities for various opiate ligands. It
would certainly be very interesting to see this outcome,
but until then, it would be premature to draw any further
conclusion based on our present findings.
CHAPTER IV SUMMARY AND CONCLUSIONS
Opium is probably one of the oldest known medication
and morphine has been known since the nineteenth century
to be the major alkaloid responsible for most of its
pharmacological and medicinal effects. Since then, large-
scale efforts were made in many laboratories to synthesize
a nonaddictive analgesic. As a result, thousands of
compounds structurally related to morphine had been made
•
and a large amount of information on the structural
requirements for analgesic action came out of this work.
It was realized that the analgesic action exists in only
one of the enantiomers of a racemic mixture, usually the
1evorotatory isomer. Furthermore, it became apparent that
parts of the morphine molecule could be altered without
major changes in pharmacological potency. On the other
hand, even small changes in certain parts of the molecule
resulted in profound effects in itspotency. The example of
such change is the substitution of the methyl group on the
N atom by an allyl group, which causes the resulting
molecule to become a specific antagonist. Some of these
antagonists retain part of their agonist properties
(e.g. nalorphine), while others are pure antagonists
(e.g. na1oxone).
The recognition of the remarkable stereospecificity
and structural constraints placed in the opiates led to
the receptor hypothesis. This hypothesis states that the
opiates must bind to specific sites on brain cells and
that this binding triggers the pharmacological responses
observed. These sites, or receptors, would permit only
drugs with suitable structures and stereochemistry to
bind. Evidence for the existence of stereospecific opiate
binding came in 1973, from 3 separate research groups
(Simon; Pert Snyder; Terenius; 1973). The discovery of
the opioid receptors in discrete localizations of the
brain sparked off an intense search for the endogenous
ligands for these receptors. Within the next 3 years, 5
endogenous compounds with opiate-like activities were
isolated from various mammalian organs, especially from
the brain and the pituitary gland. These include the 2
enkephalins (Hughes and Kosterlitz, 1975) and the 3
endorphins (Li; Guillemin ;Ling; 1976). They are all pep¬
tides, consisting between 5 to 31 amino acid residues.
The 2 enkephalins and- and endorphins are indis¬
tinguishable in their activity from morphine, whereas-
endorphin is 5-10 times more potent than morphine in
several opiate-binding assays (Guillemin, 1977). In addi¬
tion, there exists another class of opioid peptides, the
dynorphins, which were identified in 1979 by Goldstein and
coworkers. Being 50x more active than —endorphin,
this peptide is by far the most potent opioid
known. The discovery of opioid receptors and of endogenous
opioid peptides, has caused much excitement in
laboratories all over the world. This was followed by a
subsequent finding that there are 3 distinct families of
opioid peptide gene products (Terenius, 1978; Bloom, 1983;
Akil, 1984) and multiple categories of opioid receptors
(Martin, 1976; Kosterlitz, 1977; Chang Cuatrecasas
1979). Since then, much information has been gathered
about the properties, distribution and the pharmacology of
the opioid peptides.
The fact that the opioid peptides mimic the opiates
almost perfectly in their effects and behave like opiates
in opiate receptor binding assays has stimulated active
research on the structural relationships between the 2
classes of compounds. It is believed that if the opiates
and opioid peptides are competing for the same receptors
in the brain, they are very likely to have some structural
and conformational similarities. Based on this hypothesis,
an investigation was carried out by using antibodies to
morphine as a model of a specific opioid receptor. First,
antibodies were produced to a receptor-selective ligand
with the aim of producing an antigen binding site that
resembles the binding site of the opioid receptor for the
ligand. Thus these antibodies can be considered equivalent
to the receptor. It seerns most probable that an opioid
peptide which binds to the receptor with high affinity
will cross-react with the antibodies. The first attempt of
this thesis was to generate a panel of monoclonal
antibodies for different active regions of the morphine
molecule. It was hoped that the binding specificity of
these antibodies would be similar to the opioid receptor
in that the antibodies would also recognize the peptides.
However, since we were unsuccessful in raising these
specific antibodies, the proposed structural study was
carried out instead by using polyclonal antisera against
morphine. Chapter II of this thesis provides a
comprehensive account of the experimental procedures
related to the production of monoclonal antibodies.
As discussed earlier in our studies, the problem of
our failure to produce monospecific antibodies for
morphine seems to lie in the instability of our hybridoma
lines. A puzzling feature observed during our work is that
a majority of the initially positive clones lost antibody
activity readily and became non-producers. Moreover,
subcloning of the positive cultures did not seem to
improve the chance of maintaining the positive clones. Up
to now, we are still unable to determine the cause of this
rather uncharacteristic behaviour (we have successfully
used a similar protocol to raise monoclonal antibodies
against low density lipoproteins and alcohol
dehydrogenase). In a recent paper, Zagon(1987) have demon¬
strated that both exogenous and endogenous opioid
substances can inhibit neoplasia growth, and that this
antitumour action can be completely blocked by the use of
the opiate antagonist, naloxone. Their results also reveal
that opioid agonists can exert a growth inhibitory effect
on tumor cells in culture and that this effect Is dose
dependent, stereospecific and blocked by naloxone. I
Perhaps, this finding may provide a probable explanation
for our present difficulties in raising a monoclonal
antibody against morphine. It is apparent that the NS-1
cell line is derived from MOPC-21, a Balcc myeloma cell
line. When this cell line Is used as the parent myeloma,
the resulting hybridomas will carry half of the
characteristics possessed by the parent cancerous cells.
It is rationalized that there may be morphine-1ike factors
present in the culture medium and that they can bind to
the morphine-specific immunoglobulins on the surface of
the hybridoma cell resulting in the inhibition of growth.
Decause of this, the morphine-antibody carrying hybridomas
may be selectively killed and thus preventing further
cloning. The proposed hypothesis can be tested by
concommitant administration of naloxone or morphine into
the culture medium to determine if they have any
modulating activities in hybridoma growth.
It has been suggested in a recent paper by Strange
(1907) that the interaction between an antigen and its
antibody is similar to the interaction between a
neurotransmitter and its receptor. It is therefore of
great interest to compare the specificity of a receptor
and an antibody directed against the .same ligand. In
I
chapter III, polyclonal antisera were generated by the
immunization of laboratory animals with a morphine-6-
succiny1-hemocyanin conjugate. The specificities of the
resulting antisera were analysed by competitive
displacement assays with a series of opiate ligands. Our
investigation was based on the hypothesis that if the
binding sites of these antibodies resemble the
conformation of the opioid receptor, it is highly likely
that they will also interact with the opioid peptides
which are known to bind to the same type of receptors. In
particular, since morphine is a potent-se 1 ective ligand,
we would expect that the antibodies may possess binding
sites similar toJA -receptor and interact with other jA-
ligands such as DAGO and -endorphin. However, this is
not the case. Apart from binding to morphine with high
affinity, our antisera exhibited no significant
interaction with the opioid peptides or their analogues.
On the other hand, some partial cross-reactivities were
observed with high concentrations of the opiate
antagonist, naloxone, and with the opiate agonist,
etorphine. Thus in short,a 1 though we were unsuccessful in
using monoclonal antibodies to evaluate our hypothesis,
the investigation carried out by polyclonal antisera
revealed that antibodies generated against morphine behave
differently from the opioid receptors in binding
specificities.
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